Literature DB >> 8944615

Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry.

E Bergers1, P J van Diest, J P Baak.   

Abstract

AIM/
BACKGROUND: Conflicting results have been reported concerning the prognostic value of DNA flow cytometric variables (DNA ploidy, DNA index, %S phase fraction) in breast cancer. Selection bias and differences in treatment may have contributed to these conflicting prognostic results. Differences in tissue processing, the number of nuclei measured, DNA histogram/cell cycle analysis, and intra-tumour heterogeneity may also have played a role. The aim of the present study was to assess intra-tumour heterogeneity of DNA flow cytometric variables in breast cancer.
METHODS: Fresh frozen specimens (n = 274) (0.3 x 0.3 x 0.3 cm) of 17 breast cancers and 167 slices, 50 microns thick, of 58 paraffin wax embedded blocks of 21 breast cancers were studied. All samples were prepared individually for DNA flow cytometry. DNA histograms were interpreted by semi-automated cell cycle analysis (MultiCycle) by two observers to avoid biased interpretation. An artificial averaged DNA histogram of each case was composed to simulate a sample prepared from whole tumour tissue.
RESULTS: With regard to DNA ploidy, classified as diploid or aneuploid, the fresh frozen and paraffin wax embedded breast cancers showed intra-tumour heterogeneity in 53% and 38% of cases, respectively. For fresh frozen and paraffin wax embedded material, respectively, six samples had to be measured to detect the highest DNA ploidy class in 71% and 86% of cases. Averaged DNA histograms showed a loss of DNA aneuploidy in 36% and 6% of fresh frozen and paraffin wax embedded samples, respectively. High intra-tumour heterogeneity (wide ranges) was found for the %S phase fraction. Average %S phase fraction and average aneuploid %S phase fraction had the widest ranges at 9.5-31.6% and 0.0-62.7%, respectively. There was no correlation between the number of stemlines and intra-tumour %S phase variability on the one hand and tumour size and grade on the other.
CONCLUSIONS: High intra-tumour heterogeneity for breast cancer was found for DNA ploidy, the DNA index and %S phase fraction as measured by flow cytometry, which may explain the conflicting prognostic results reported in the literature. To detect aneuploid cells, six samples may have to be prepared and measured separately. Measurement of these variables may be more reliable in paraffin wax sections because the thick slices provide a more representative sample. Prospective studies are required to determine whether the highest %S phase fraction value or the average value is more useful in the clinical context.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8944615      PMCID: PMC500835          DOI: 10.1136/jcp.49.11.931

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  26 in total

1.  Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.

Authors:  G M Clark; L G Dressler; M A Owens; G Pounds; T Oldaker; W L McGuire
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

2.  Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity.

Authors:  O P Kallioniemi
Journal:  Cytometry       Date:  1988-03

3.  Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer.

Authors:  O P Kallioniemi; T Hietanen; J Mattila; M Lehtinen; K Lauslahti; T Koivula
Journal:  Eur J Cancer Clin Oncol       Date:  1987-03

4.  Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer.

Authors:  O P Kallioniemi; G Blanco; M Alavaikko; T Hietanen; J Mattila; K Lauslahti; M Lehtinen; T Koivula
Journal:  Cancer       Date:  1988-11-15       Impact factor: 6.860

5.  DNA ploidy and survival in breast cancer patients.

Authors:  C J Cornelisse; C J van de Velde; R J Caspers; A J Moolenaar; J Hermans
Journal:  Cytometry       Date:  1987-03

6.  Heterogeneity of breast carcinomas determined by flow cytometric analysis.

Authors:  M U Prey; J S Meyer; K R Stone; R W McDivitt
Journal:  J Surg Oncol       Date:  1985-05       Impact factor: 3.454

7.  The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer.

Authors:  H B Muss; T E Kute; L D Case; L R Smith; C Booher; R Long; L Kammire; B Gregory; J K Brockschmidt
Journal:  Cancer       Date:  1989-11-01       Impact factor: 6.860

8.  DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast.

Authors:  A D Baildam; J Zaloudik; A Howell; D M Barnes; L Turnbull; R Swindell; M Moore; R A Sellwood
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

9.  Tumour DNA ploidy as an independent prognostic factor in breast cancer.

Authors:  O P Kallioniemi; G Blanco; M Alavaikko; T Hietanen; J Mattila; K Lauslahti; T Koivula
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

10.  Tumour aneuploidy, prognostic parameters and survival in primary breast cancer.

Authors:  A A Owainati; R A Robins; C Hinton; I O Ellis; C S Dowle; B Ferry; C W Elston; R W Blamey; R W Baldwin
Journal:  Br J Cancer       Date:  1987-04       Impact factor: 7.640

View more
  14 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  Neuronal DNA content variation (DCV) with regional and individual differences in the human brain.

Authors:  Jurjen W Westra; Richard R Rivera; Diane M Bushman; Yun C Yung; Suzanne E Peterson; Serena Barral; Jerold Chun
Journal:  J Comp Neurol       Date:  2010-10-01       Impact factor: 3.215

3.  Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.

Authors:  A E Pinto; S André; J Soares
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

4.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints.

Authors:  J Torhorst; C Bucher; J Kononen; P Haas; M Zuber; O R Köchli; F Mross; H Dieterich; H Moch; M Mihatsch; O P Kallioniemi; G Sauter
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

5.  Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma.

Authors:  A E Pinto; S André; T Pereira; S Nóbrega; J Soares
Journal:  J Clin Pathol       Date:  2001-07       Impact factor: 3.411

6.  Prognostic relevance of DNA flow cytometry in breast cancer revisited: The 25-year experience of the Portuguese Institute of Oncology of Lisbon.

Authors:  António E Pinto; Teresa Pereira; Giovani L Silva; Saudade André
Journal:  Oncol Lett       Date:  2017-02-13       Impact factor: 2.967

7.  Cell proliferation parameters and apoptosis indices in pituitary macroadenomas.

Authors:  R M Ruggeri; G Costa; A Simone; A Campennì; A Sindoni; A Ieni; V Cavallari; F Trimarchi; L Curtò
Journal:  J Endocrinol Invest       Date:  2011-09-06       Impact factor: 4.256

Review 8.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

9.  Gross genomic damage measured by DNA image cytometry independently predicts gastric cancer patient survival.

Authors:  J A M Belien; T E Buffart; A J Gill; M A M Broeckaert; P Quirke; G A Meijer; H I Grabsch
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

Review 10.  Taxane benefit in breast cancer--a role for grade and chromosomal stability.

Authors:  Roger P A'Hern; Mariam Jamal-Hanjani; A Marcell Szász; Stephen R D Johnston; Jorge S Reis-Filho; Rebecca Roylance; Charles Swanton
Journal:  Nat Rev Clin Oncol       Date:  2013-05-07       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.